Oppenheimer Rates Eupraxia Pharmaceuticals (EPRX) buy

Oppenheimer maintains its buy stance on EPRX, targeting a $17 price, a 165.21% upside from the current price.

By EarningsIQ Research Desk · Published Jun 26, 2026, 10:01 AM EDT · Updated Jun 27, 2026, 2:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Oppenheimer rated Eupraxia Pharmaceuticals Inc. ($EPRX) "buy" with a $17 price target on June 26, 2026.

Since the rating, $EPRX is down 1.2% after 1 week, down 6.5% after 1 month and up 0.3% to date (from the $6.60 close on Jun 26, 2026).

EPRX Eupraxia Pharmaceuticals Inc.

$6.62 -12.55% year to date

Daily close · Oct 16, 2026

Key Points

Oppenheimer reiterated its buy rating on EPRX, setting a price target of $17 on June 26, 2026.
Oppenheimer's $17 price target implies 165.21% upside from Eupraxia Pharmaceuticals Inc.'s ($EPRX) current $6.41 share price.
EPRX shares traded at $6.41 on Friday, reflecting ongoing interest from analysts.
Institutional activity in EPRX includes a 429.7% increase by Affinity Asset Advisors, LLC, now holding 1,589,005 shares.

Get $EPRX trade alerts by text

We text you when insiders, Congress or big funds trade $EPRX. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Eupraxia Pharmaceuticals Inc. alert may contain errors. Disclosures

Oppenheimer has reaffirmed its buy rating for EPRX, maintaining a target price of $17. This reiteration, made by analyst Jay Olson on June 26, 2026, signals continued confidence in the company's prospects.

Analyst rating track record

Oppenheimer vs. the S&P 500

YTD return +30.18% hypothetical

All-time return +103.01% S&P 500 +28.12%

vs. S&P 500 +74.89% ahead of the index

Hypothetical returns from Oppenheimer's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in EPRX

Several institutional investors have recently adjusted their positions in EPRX. Beutel, Goodman & Co Ltd. slightly reduced its holdings by 42,908 shares, now holding a total of 3,666,465 shares valued at approximately $26.4 million. On the other hand, Affinity Asset Advisors, LLC significantly increased its stake by 1,289,005 shares, marking a 429.7% rise, and now holds 1,589,005 shares worth about $11.5 million. Scotia Capital Inc. also boosted its position by 55,995 shares, a 4.4% increase, bringing its total to 1,342,178 shares valued at $7.2 million. Ikarian Capital, LLC expanded its holdings by 604,741 shares, achieving a 99.1% increase, resulting in 1,214,741 shares valued at approximately $8.8 million.

Analysts Set New Price Targets

On June 26, 2026, Oppenheimer reiterated its buy rating on EPRX with a $17 price target. Other analysts also shared positive outlooks: Stifel initiated coverage with a buy rating and a $25 target on May 21, 2026. Earlier in the year, HC Wainwright & Co. maintained its buy rating with an $11 target on March 17, 2026, and Cantor Fitzgerald maintained a buy rating with a $19 target on January 15, 2026.

About EPRX

EPRX is a company that operates in the healthcare sector, focusing on the development and commercialization of pharmaceuticals. The company aims to address unmet medical needs by offering innovative treatments. With its headquarters located in the United States, EPRX continues to explore new opportunities in the pharmaceutical industry.

Bottom Line

Oppenheimer's reaffirmation of its buy rating on EPRX with a $17 target on June 26, 2026, highlights the firm's positive outlook on the company's potential. EPRX's stock remains a point of interest for analysts and institutional investors alike. As always, it's important for investors to consider that these ratings are based on past data and may not reflect current market conditions.

12-month forecast